59 results
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
will 1 long term undergo multiple lines of systemic therapy over the course of their disease 1 2 *Incidence of BRAF alterations varies across pLGG subtypes … Significant Long-Term Consequences Surgery Chemotherapy Radiation Significant recovery times Requirement for indwelling Risk of secondary malignancy catheter
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
12 Jun 24
Regulation FD Disclosure
8:07am
of disease recurrence, most patients will 1 long term undergo multiple lines of systemic therapy over the course of their disease 1 2 *Incidence of BRAF … To Childhood And Can Have Significant Long-Term Consequences Surgery Chemotherapy Radiation Significant recovery times Requirement for indwelling Risk
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
of disease recurrence, most patients will 1 long term undergo multiple lines of systemic therapy over the course of their disease 1 2 *Incidence of BRAF … To Childhood And Can Have Significant Long-Term Consequences Surgery Chemotherapy Radiation Significant recovery times Requirement for indwelling Risk
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
., de Palma L., Mastronuzzi A., Pro S., Colafati G.S., Boni A., Della Vecchia N., Velardi M., Evangelisti M., et al. Short and Long-Term Toxicity … To Childhood And Can Have Significant Long-Term Consequences Goal of therapy is to control the tumor, minimize the burden of surgery, chemotherapy
8-K
EX-99.1
z6l1vc
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
1urc6 zhhfn
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
rbp38bdsuxqa7t4
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
ovwate d4
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
wea1v1tcj1p wb
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-99.2
omx0vyq3 v2duu1
17 Nov 23
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
7:07am
8-K
EX-99.2
11sqj9f96ho4dd 36
6 Nov 23
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
0kbyb9f
30 Oct 23
Regulation FD Disclosure
8:12am
S-3ASR
p9s7ifmamlfkdsayd
14 Sep 23
Automatic shelf registration
5:28pm
8-K
EX-99.1
qvl plua1
11 Sep 23
Regulation FD Disclosure
8:35am
8-K
EX-99.2
ch8shj6stjcjt906w4d4
11 Sep 23
Regulation FD Disclosure
8:35am
8-K
EX-99.2
kth5kd wd1mbjwcz3
16 Aug 23
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
8:06am